Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …

Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

PURPOSE Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which
leads to ligand-independent constitutive activation that is not inhibited by anti-androgen …

Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

Purpose We reported previously that the detection of androgen receptor splice variant-7 (AR-
V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of …

BACKGROUND Metastatic prostate cancer is a common and lethal disease for which there
are no therapies that produce cures or long‐term durable remissions. Clinically relevant …

Prostate cancer is the most commonly diagnosed cancer among men in the Western world.
Although localized disease can be effectively treated with established surgical and …

Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development
and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a …

The role of androgen receptor (AR) activation and expression is well understood in prostate
cancer. In breast cancer, expression and activation of AR is increasingly recognized for its …